Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belumosudil versus best available therapy for refractory or recurrent chronic graft-versus-host disease
2026-525913-30-00Phase 3Authorised
- Sponsor
- Sanofi
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 33
01
Overview
Phase 3, randomised, open-label trial of belumosudil in chronic graft-versus-host disease (cGVHD) (2 arms), sponsored by Sanofi. Primary endpoint: Overall response rate. Planned start Oct 2026; status: authorised.
02
Drugs
belumosudil
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on 2026-525913-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525913-30-00.